Ask AI
ProCE Banner Activity

Schizophrenia Care Is Evolving: An Expert-Led FAQ About Muscarinic Therapy

Clinical Thought

The landscape of schizophrenia care is changing. Antipsychotic use carries with it the risk of adverse effects, including the development of drug-induced movement disorders as a result of the dopamine blockade they create. This expert-led FAQ highlights developments in muscarinic agonist pathways that circumvent this dopamine blockade and offer a promising safety profile. Learners will gain clarity on safety and efficacy, patient selection, FDA-supported recommendations on usage, and insights into supporting clinical trials. This activity empowers healthcare professionals with the knowledge needed to expand their current practice with improving patient outcomes at the forefront.

Released: August 18, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb. 

Bristol Myers Squibb

Target Audience

This program is intended for healthcare professionals caring for patients with schizophrenia including psychiatrists, physicians, nurse practitioners, physician associates, registered nurses, pharmacists, social workers, and psychologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the clinical utility of novel antipsychotics to address unmet needs of current schizophrenia treatments

  • Define the distinctive mechanisms of action and pharmacokinetic characteristics of novel and emerging therapeutic agents for schizophrenia that extend beyond traditional antidopaminergic approaches

  • Integrate novel therapeutic options into treatment plans for appropriate patients with schizophrenia based on current clinical evidence

  • Counsel patients on optimal administration and side effect management for schizophrenia therapies to maximize adherence

  • Design strategies to holistically assess the range symptoms in schizophrenia and the impact of therapy on patient outcomes

Financial Disclosures

Primary Author

Leslie Citrome, MD, MPH: consultant: AbbVie, Acadia, AdhereTech, Alkermes, Altus, Alumis, Arc, Auritec, Autobahn, Avant Healthcare Solutions, Axsome, Biogen, BioXcel, Bristol Myers Squibb/Karuna, Boehringer Ingelheim, Cadent, Cerevel, Clario/Medavante/Prophase, Clinilabs, Compass, Corcept, Definium, Delpor, Eisai, Enteris BioPharma, Health Wellness Partners, HLS Therapeutics, Idorsia, INmune Bio, Intra-Cellular, Johnson & Johnson/Janssen, Little Bear, Lundbeck, Luye, Lyndra, MapLight, Marvin, Mindmed, Neumora, Neurocrine, Neurelis, Neushen, Noema, Novartis, Noven, Orexo, Otsuka, Ovid, Pontifax/Draig, Praxis, PSL, Real Chemistry, Relmada, Renew Research, Response, Reviva, Sage, Seaport, Sumitomo/Sunovion, Supernus, Teva, Vanda; speaker: AbbVie, Acadia, Alkermes, Bristol Myers Squibb, Eisai, Idorsia, Intra-Cellular, Johnson & Johnson/Janssen, Lundbeck, Luye, Neopharm, Neurocrine, Noven, Otsuka, Recordati, Takeda, Teva, Vanda; individual publicly traded stock/stock options: Reviva.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.